2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether

Dermal absorption

Administrative data

Endpoint:

dermal absorption in vivo

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Published data

Data source

Reference

Title:

Human in vivo percutaneous absorption of Pyrethrin and Piperonyl Butoxide

Author:

Wester, R.C., Bucks, D.A.W., Maibach, H.I.

Year:

1994

Bibliographic source:

Food Chem Toxicol. 32, 51-53

Materials and methods

Principles of method if other than guideline:

The dermal absorption of the active substance applied with a formulation containing 3% Piperonyl butoxide was studied by Wester et al.(1994)
14C-labelled Piperonyl butoxide (3.4 mCi/mmol - equivalent to a dose of 75.8 µg Piperonyl butoxide/ cm²) was applied to the ventral forearms of six human volunteers .
Percutaneous absorption was determined by 14C urinary excretion.
The forearms were thoroughly cleaned with soap and water 30 minutes after application. Percutaneous absorption was determined by urinary cumulative excretion of the 14C-radiolabel following application of the above dose.

GLP compliance:

not specified

Test material

Test material information

Constituent 1

Reference substance name:

Piperonyl butoxide

IUPAC Name:

Piperonyl butoxide

Details on test material:

14C-labelled Piperonyl butoxide (3.4 mCi/mmol

Radiolabelling:

yes

Test animals

Species:

human

Sex:

male

Administration / exposure

Type of coverage:

not specified

Vehicle:

other:

Doses:

3.4 mCi/mmol - equivalent to a dose of 75.8 µg Piperonyl butoxide/ cm²

No. of animals per group:

6 male volunteers

Control animals:

no

Details on study design:

100 µl of a formualtion containing pyridine and piperonyl butoxide were applied to the foreamr (44cm²)

Results and discussion

Signs and symptoms of toxicity:

not specified

Dermal irritation:

not specified

Absorption in different matrices:

no data

Total recovery:

no data

Percutaneous absorption

Dose:

75.8 µg/ cm²

Parameter:

percentage

Absorption:

2.1 %

Remarks on result:

other: 24 h

Conversion factor human vs. animal skin:

no applicable

Any other information on results incl. tables

Dermal absorption of Piperonyl butoxide was determined to be 2.1±0.6% of the dose applied to ventral forearm skin of six male volunteers. The calculated half-life for¹⁴C excretion of Piperonyl butoxide was 32 h.

Applicant's summary and conclusion

Conclusions:

Dermal absorption was 2.1% in a human volunteer study.

Executive summary:

The dermal absorption of the active substance applied with a formulation containing 3% Piperonyl butoxide was studied by Wester et al.(1994) who applied ¹⁴C-labelled Piperonyl butoxide (3.4 mCi/mmol - equivalent to a dose of 75.8 µg Piperonyl butoxide/ cm²) to the ventral forearms of six human volunteers .

The forearms were thoroughly cleaned with soap and water 30 minutes after application. Percutaneous absorption was determined by urinary cumulative excretion of the ¹⁴C-radiolabel following application of the above dose.

In this study the dermal absorption of Piperonyl butoxide was determined to be 2.1±0.6% of the dose applied to ventral forearm skin. The calculated half-life for ¹⁴C excretion of Piperonyl butoxide was 32 h.